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Prognostic factors and prognostic models play a key role in medical research and patient
management. The Nottingham Prognostic Index (NPI) is a well-established prognostic clas-
sification scheme for patients with breast cancer. In a very simple way, it combines the infor-
mation from tumor size, lymph node stage and tumor grade. For the resulting index
cutpoints are proposed to classify it into three to six groups with different prognosis. As not
all prognostic information from the three and other standard factors is used, we will consider
improvement of the prognostic ability using suitable analysis approaches.
Methods and Findings
Reanalyzing overall survival data of 1560 patients from a clinical database by using multi-
variable fractional polynomials and further modern statistical methods we illustrate suitable
multivariable modelling and methods to derive and assess the prognostic ability of an index.
Using a REMARK type profile we summarize relevant steps of the analysis. Adding the
information from hormonal receptor status and using the full information from the three NPI
components, specifically concerning the number of positive lymph nodes, an extended NPI
with improved prognostic ability is derived.
Conclusions
The prognostic ability of even one of the best established prognostic index in medicine can
be improved by using suitable statistical methodology to extract the full information from
standard clinical data. This extended version of the NPI can serve as a benchmark to
assess the added value of new information, ranging from a new single clinical marker to a
derived index from omics data. An established benchmark would also help to harmonize the
statistical analyses of such studies and protect against the propagation of many false
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promises concerning the prognostic value of new measurements. Statistical methods used
are generally available and can be used for similar analyses in other diseases.
Introduction
Understanding and improving the prognosis of patients with a disease or health condition is a
priority in clinical research and practice. In the PROGnosis RESearch Strategy (PROGRESS)
series a framework to improve research of interrelated prognosis themes has been proposed
[1–4]. Two of the key topics are the role of prognostic factors and prognostic models. Since the
beginning of the century, much of the research has been focused on issues related to personal-
ized or stratified medicine with the assessment of genetic markers and analyses of high dimen-
sional data as the challenge for researchers in many disciplines. A substantial part of such
studies investigates issues for patients with cancer, breast cancer thereby being the disease con-
sidered most often [5–11]. Unfortunately, most of the results from the very large number of
individual studies have not been validated and the number of clinically useful markers is piti-
fully small [12–14]. There are many potential pitfalls inherent in the complex process of suc-
cessfully developing and validating a marker from omics data [15].
For some years it has been discussed to improve prediction rules through the integration of
clinical and gene expression data [5,16–20]. However, applying combined prediction rules at a
broader level would cause difficulties in many (smaller) centers and increase costs. Obviously,
to be cost effective the predictive value of a combined prediction rule would need to be much
larger than the predictive value of rules based on some generally available clinical measure-
ments. In other terms, the added value of the genetic information would need to be ‘substan-
tial’. Yet, assessing the added predictive value of genetic data to clinical data is far from trivial.
Boulesteix and Sauerbrei [21] critically discuss various approaches for the construction of com-
bined prediction rules and review procedures that assess and validate the added predictive
value. Obviously, adding predictive value from genetic information to a ‘good’ clinical model is
much more difficult than adding value to a ‘less good’ clinical model. Knowing about difficul-
ties in using a combined model in practice, it follows that one may try to ‘optimize’ the predic-
tive value from a model based on clinical data. The use of a combined predictor would only be
sensible if the genetic information adds substantial predictive value to such an ‘optimized’ clini-
cal predictor.
Notation in this area of research is confusing. Despite of using terms like ‘prediction’ and
‘added predictive value’ we will not consider the role of ‘predictive factors’, a term popular in
cancer research where it usually implies that a factor is relevant for treatment decision. Such
aspects require additional investigations (for example analysis of subgroups or investigation for
an interaction between treatment and a factor) which will not be considered here [4]. This
paper concentrates on prognostic factors and prognostic models [2,3]. The latter is a formal
combination of multiple prognostic factors and the term predictor is popular and will be used
here.
A number of prognostic models are published for many diseases, but for practical use the
situation is often confusing. For example, there are over 100 models for prostate cancer [22]
and for chronic kidney disease Collins et al [23] identified 14 prediction models featuring 43
different risk predictors. However, in breast cancer the situation seems to be better than for
most other areas. Similar to the other cases, many classification schemes have been proposed,
most of which did not survive validation [24,25]. But more than 30 years ago, the Nottingham
Prognostic Index (NPI) was proposed, has been sufficiently validated, is well accepted and also
used in clinical practice [26]. The three components lymph node stage, grade and tumor size
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are combined to a continuous index. Originally two and later up to five cutpoints were pro-
posed to create three to six categories with different prognosis [26,27]. The simplicity of the
NPI is certainly an important criterion for its clinical relevance, but it also implies that some
prognostic information may not be used to improve the NPI. Applying elaborated statistical
methods–we explain the key ideas and cite relevant references but do not provide all details—
to a clinical registry data set [28] we extract the full information of the data and derive a modi-
fied version of the NPI with improved prognostic ability. We will illustrate that the continuous
variables tumor size and number of positive nodes exhibit more information and will investi-
gate whether another six standard variables carry prognostic information in addition to the
NPI. With overall survival as the outcome of interest we will use the Cox model [29] for analy-
sis. An often neglected but relevant issue is the verification of the model assumptions. We will
check whether important assumptions of the Cox proportional hazard model are acceptable or
whether modifications are required. A fundamental assumption is the proportionality of the
hazard functions [30]. As known for many other diseases, prognostic effects varying in time
have also been shown for clinical [31,32] and for genetic data [7,33] in breast cancer research.
Nevertheless, even in top-ranking cancer journals it is rather an exception to report the check
of this important assumption [34,35] and we speculate that suitable checks have often not been
conducted. There is a severe danger of misspecification and models derived may be (partly)
wrong with a potential consequence of incorrect medical decisions. However, poor reporting
prevents to assess whether a relevant check of the model was not done or just not reported. To
improve on this aspect several reporting guidelines, of which TRIPOD [36] and REMARK [37]
are most relevant for the type of study discussed here, have been developed. They aim to
Enhancing the QUAlity and Transparency Of health Research (EQUATOR network).
As discussed in the PROGRESS series [1–4] it is important having a suitable prognostic
index with good discriminative ability for many diseases. Larger data bases with standard clini-
cal information are often available and prognostic indices exhibiting the full information from
the data could be derived in a similar manner as done here. Using the NPI as an example we
illustrate how to derive an index for a survival time outcome and how to assess its prognostic
ability. In order to increase readability and understandability of the various analyses we will
provide a technical summary of the study similar to the REMARK profile [38].
A ‘good’ predictor summarizing the standard information from clinical data can be used as
a suitable benchmark to assess the added value of new information. In the context of research
such a benchmark would be highly relevant for the discussion about clinical predictors, molec-
ular predictors or combined predictors. Compared to a ‘good’ clinical predictor as an adequate
benchmark it is more difficult for a molecular predictor or a combined predictor to substan-
tially increase the discriminative ability. This will influence the role of predictors in patient
management. In section 2 we introduce the data, section 3 introduces the statistical methods
used to derive multivariable prognostic models and to assess the prognostic ability of a model.
In section 4 we present results and propose an extended version of the NPI. Although it needs
only information about hormone receptor status in addition to the three original NPI compo-
nents, it has much larger discriminative ability than the NPI. With the main emphasize on the
importance of a ‘standard’ prognostic index, methodological issues to derive such an index and
its clinical relevance, we discuss our findings in section 5.
Methods and Data
Data
All patients had primary surgery for breast cancer between January 1984 and December 1998
at the surgical clinic of the Charité hospital in Berlin and were followed up until 2007. Nearly
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all of them were operated by the first author and he had them included in a clinical database,
consisting of 2062 cases. In order to define a more homogeneous and sensible patient popula-
tion for analysis, we had defined several inclusion and exclusion criteria. Accordingly, we
excluded 502 patients, leaving 1560 patients for the analysis. Main reasons for exclusion were
breast cancer in situ (n = 134) and age older than 80 years (n = 123), further reasons are briefly
summarized in the REMARK type profile (Table 1) and details can be found in Winzer et al
[28]. We use data from clinical follow-up and consider overall survival (OS) with all causes of
death as an event. The number of events for OS is 221. During 1984 and 1998 treatment of
patients changed severely worldwide. Winzer et al [28] provide details about treatment strate-
gies in three periods (1984–1990, 1991–1993, 1994–1998). During the first period, most of the
patients (73.4%) had a mastectomy (±) radiotherapy and did not receive adjuvant treatments.
In the third period 61% had breast conserving treatment (±) radiotherapy and a systemic treat-
ment. For details of local and adjuvant therapy, measurement techniques of prognostic factors,
influence of prognostic factors on choice of treatment and further details concerning follow-
up, we refer to Winzer et al [28] and cited references. To account for different treatment strate-
gies, all Cox models were stratified according to therapy strata.
The study was retrospective and we did not obtain informed consent from the patients.
However, only anonymized data is used. There was no necessity to contact an Ethical Commit-
tee for this re-analysis of data. The patient records were not de-identified before entry in the
original database. However, before starting the first analysis [28] KJW had received a positive
vote by the authorized local data protection person for an analysis of the data base from breast
cancer patients of the Charité Hospital. In addition this positive vote allows comparing follow-
up data with the information given in the cancer registry and data from the residence registra-
tion office in Berlin. It is signed by Heiko Wiese and dated May 16 2012. KJW sent the database
to AB to subtract the relevant information. AB created a subfile which was used in the earlier
paper [28] and in this new analysis. Information specifically referring to the patient (such as
name and address) was not stored. Specific dates (such as birthday or date of surgery) were
only used to create relevant information such as age, survival time or year of surgery but will
not be included in the publicly available file. This file will only include all variables mentioned
in Table 1 for the 1560 patient included in the analysis. To destroy the chronological order of
patients’ entry in the database AB randomized the order of patients’ records in the publicly
available file. With these procedures we protect against identification of individual patients
while allowing conducting analyses presented. KJW and AB have separate lists allowing them
to restore patient identification.
The distribution of the nine standard prognostic factors and of treatment is given in S1
Table. Tumor grade has a larger percentage of missing data (13.9%) and some of the other fac-
tors have missing data in a smaller percentage of patients. In order to use all patients for the
multivariable analysis we imputed missing data in two steps. In a first step, missing informa-
tion was replaced based on clinical criteria (related clinical factors), if applicable. Since this
strategy was not very successful, it was decided to drop all observations with more than three
missing values in the standard prognostic factors (N = 2) and impute the remaining missing
values using single univariable imputation sampling [39] based on observed survival times. In
all analyses we will use the data after imputation for missing information (N = 1560). The dis-
tribution of the resulting NPI is given in S1 Fig. As nodes and grade both contribute with 1 to 3
points to the Nottingham Prognostic Index, the resulting distribution of the NPI has several
peaks.
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Table 1. REMARK type profile.
a) Patients, treatments and variables
Study and marker Remarks
Markerhandled M = NPI Continuous and categorical. Cutpoints as predeﬁned in the literature. For details see
Blamey et al [27].
Further variables v1 = Tumor Size, v2 = No. of pos. Lymph Nodes, v3 = Tumor Grade, v4 = Age, v5 = Histology,
v6 = Hormone Receptor Status, v7 = Menopausal Status, v8 = Vessel Invasion, v9 = Lymphatic
Vessel Invasion
Patients n Remarks
Assessed for eligibility 2062 Disease: Primary Breast Cancer Patient source: Database Surgical clinic Charité,
Berlin. All patients with surgery from 1st Jan. 1984 to 31st Dec. 1998.
Excluded 502 63 metastasis, 73 previous carcinoma other than breast cancer, 86 primary breast
cancer prior to the study, 134 breast cancer in situ, 8 pt0, 123 older than 80 years, 20
neo-adjuvant chemotherapy, 71 death within ﬁrst months of surgery, three or more
standard prognostic factors missing. For some patients, more than one exclusion
criterion applied.
Included 1560 Previously untreated. Treatment: Local therapy: BCT or mastectomy with or without
radiotherapy, adjuvant therapy: chemo (y/n), hormone (y/n). For details see Add ﬁle 1
and Table 2 in Winzer et al [28]
With outcome events 221 Overall survival: death from any cause
b) Statistical analyses. All analyses using a Cox model are stratiﬁed for strata according to therapy. There are 8 strata deﬁned by the combination of
surgery, radiotherapy (y/n) and systemic therapy (y/n (no chemotherapy and no hormone therapy))
Analysis Patients Events Variables considered Results/ remarks
IDA 11: Imputation for missing values 1560 NR 2 v1(94), v2 (68), v3(217), v6
(490), v7(54)
Variables (number of patients) with imputed
values
A13: NPI (3) 1560 221 NPI Prognostic value of NPI in 3 categories
(Table 2, Fig 1, Table 3)
A2: NPI (6) 1560 221 NPI 6 categories (Fig 1, Table 3)
C14: Check of PH5 in NPI (3) and in NPI (6) 1560 221 NPI Fig 2, S2 Fig and non-signiﬁcant result of FPT
(see last paragraph 4.2).
A3: NPIcont. 1560 221 NPI More information from continuous data?
(Table 3)
C2: NPIcont. has a linear effect 1560 221 NPI FP2 function not signiﬁcantly better, see 4.3.1
C3: Check of PH5 in NPIcont. 1560 221 NPI Non-signiﬁcant result of FPT (see last
paragraph 4.3.1)
A4: MFP6 of the three NPI variables (univ. and
multivariable)
1560 221 v1, v2, v3 Table 4
A5: Functional form for nodes 1560 221 v2 Fig 3
A6: Prognostic value and additional value of further
variables (univ. and multiv.)
1560 221 NPI, v4, v5, v6, v7, v8, v9 Table 5, Fig 4
A7: MFP using all available information 1560 221 v1, v2, v3, v4, v5, v6, v7,
v8, v9
Final MFP model in Table 6, see 4.5
A8: Measures of separation 1560 221 NPI, v1, v2, v3, v4, v5, v6,
v7, v8, v9
Table 7, see 4.6
C4: Check of PH5 in MFP model 1560 221 v1, v2, v3, v6 Non-signiﬁcant result of FPT (see end of 4.5)
REMARK type proﬁle providing an overview of the patient population, variables in the study and analyses conducted. The Nottingham Prognostic Index
(NPI) is the marker of main interest. NPI(3) and NPI(6) denote classiﬁcations into 3 and 6 prognostic groups, respectively.
1 Initial data analysis
2 not relevant
3 Ai–analysis no. i
4 Ci–check number i of an assumption
5 Proportional hazards assumption of the Cox model
6 Multivariable Fractional Polynomial procedure
doi:10.1371/journal.pone.0149977.t001
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Nottingham Prognostic Index
The three components lymph node stage (LN), grade and tumor size are combined to the
index
NPI ¼ LNð1 3Þ þ Grade ð1 3Þ þ maximum diameter ðcmÞ  0:2;
where LN is a categorized version of the number of positive lymph nodes (1 –zero positive
nodes, 2 –one to three positive nodes, 3 –four or more positive nodes). In our data, this gives
an observed range of NPI from 2.02 (LN negative, grade 1, 0.1 cm) to 8.2 (LN Stage 3, grade 3,
size 11.0cm) Originally the two cutpoints 3.4 and 5.4 and later up to five cutpoints (2.4, 3.4, 4.4,
5.4 and 6.4) were proposed to create three to six categories with different prognosis [26,27].
Here, we will use the notation NPIcont to refer to the continuous values of NPI, NPI(3) and
NPI(6) for classification schemes with three or six prognostic groups. For the three NPI(3)
groups we will use the abbreviations NPI(3)-1, NPI(3)-2 and NPI(3)-3, with NPI(3)-1 denoting
the group with the best prognosis. The six prognostic groups from NPI(6) will be denoted as in
Blamey et al [27]: Excellent Prognostic Group (EPG) with an observed NPI range of 2.08–2.4,
Good (GPG) 2.42 to 3.4; Moderate I (MPG I) 3.42 to 4.4, Moderate II (MPG II) 4.42 to 5.4,
Poor (PPG) 5.42 to 6.4 and very poor (VPG) 6.42–8.2.
The Cox Model
The Cox proportional hazard model was used to estimate the effect of variables and to derive
multivariable models [29]. As any regression model, the Cox model makes several important
assumptions, including proportional hazards and linear relationships between continuous
covariates and the log hazard function. It is well-known that assumptions are often violated
and the importance to check for them is stressed in the REMARK guidelines [38] and in many
other papers and books. For studies with long-term follow-up the proportional hazard (PH)
assumption is often critical, for example when a portion of patients can be considered cured
after having survived for a longer period. To check the PH assumption for a categorical variable
plots of log(-log survival time) versus log time may be used. They should be approximately par-
allel [40]. Other approaches investigate whether a Cox model with an extension for time-vary-
ing effects fit the data significantly better. Such approaches investigate for a potential
interaction of a covariate with time. We will use the fractional polynomial time (FPT) algo-
rithm [41] which was developed to detect and model potential time-varying effects with a sig-
nificance level of 1%. The decision to use FPT is based on personal preferences and results of a
comparison of several approaches [42].
We will use the class of fractional polynomials (FPs) to investigate whether the popular
assumption of a linear effect is acceptable or whether a non-linear function improves the data
fit severely and is therefore an important argument against the linearity assumption [43]. For
categorical variables with an ordinal scale (such as tumor grade) we will use ordinal dummy
coding and allow collapsing two neighboring categories in the model building process. For
details see chapter 3.3 in [43] Royston and Sauerbrei.
For our registry data it is not possible to get unbiased estimates of effects for different treat-
ments. However, as stressed in the REMARK guidelines (Item 10 f and Item 17) [38], it is
important that different treatments are accounted for in the analysis. Details about treatment
modalities and arguments to consider, type of surgery (mastectomy or breast conserving ther-
apy) and the application of radiotherapy (yes, no) and systemic therapy (yes, no) as the three
most relevant aspects of treatment given, are discussed in Winzer et al [28]. To account for
therapy we stratified all analyses with the Cox regression model for the eight strata defined by
the combination of the three binary variables.
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Multivariable Fractional Polynomials to Model Continuous Variables
A method for variable selection is required when a larger number of variables need to be
assessed for their influence on an outcome of interest. For each continuous variable it is
also necessary to estimate their influence by considering a (non-linear) functional form.
Assuming a linear function or categorizing the continuous variable and using step-func-
tions are the preferred approaches in medicine. However, severe weaknesses of both
approaches have been known for a long time. For details see Box 4 of the REMARK guide-
lines [38]. To avoid the severest weaknesses, the class of fractional polynomials and the cor-
responding function selection procedure (FSP) have been proposed [43,44]. To derive a
multivariable regression model, the multivariable fractional polynomial (MFP) procedure,
which combines the fractional polynomial FSP with the backward elimination procedure
for variable selection, has gained popularity in the health sciences. Deriving a multivariable
prognostic model for patients with breast cancer, details of the procedure are given [45],
key parts of the philosophy to prefer MFP to other multivariable approaches are discussed
and illustrated [43,46].
In order to select a MFP model, the significance level is the key parameter to determine the
number of variables included and the complexity of functional forms for continuous variables.
For both parts we will use the popular 5% level, denoted as MFP(0.05, 0.05).
Discriminative Ability of a Model
Kaplan-Meier plots are a popular and simple way to assess the discriminative ability of a classi-
fication scheme. However, such plots do not give an overall measure and it is difficult to com-
pare several classification schemes. If a continuous score is categorized by using various
cutpoints it is easily possible to present plots which can be very misleading. Differences of
estimated survival rates depend heavily on the chosen cutpoint(s) and by creating smaller sub-
groups at both ends of a prognostic score, Kaplan-Meier plots may indicate extreme differences
between subgroups. Specifically if the numbers of patients at risk are not given, such plots bear
the risk of severe misinterpretation. The REMARK guidelines [38] (see item 15) explicitly state
that numbers at risk should be provided for selected time points. We will present Kaplan-
Meier plots for NPI(3) and NPI(6).
Based on the idea of measuring the separation between several Kaplan–Meier curves and
simultaneously taking into account the relative frequencies of each category, the D-statistic
was proposed [47]. It assumes that the proportional hazards assumption is not seriously
violated, otherwise the use of this measure is doubtable. The D statistic can be transferred
to a R2-type measure of explained variation. D and R2D have been chosen because the latter
‘appear to be the best overall’ in a large simulation study comparing 17 R2-type measures
proposed for survival models [48]. In addition we will use the c-index. It was chosen
because it has been well known for a long time and it seems to be the measure used most
often. However, for survival data it has some weaknesses and it is preferable to use a modi-
fied version [49].
Software
Analyses were conducted with Stata/SE 13.1 [50] and some user-written Stata programs were
used for imputation of missing values [39], calculation of explained variation [51] and Cox
models with time-varying effects (stmfpt, available at https://portal.uni-freiburg.de/imbi/
Royston-Sauerbrei-book).
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Results
To provide an overview of analyses conducted and reasons for them, we summarize this infor-
mation in the bottom part of the REMARK type profile (Table 1).Information about the initial
data analysis (IDA 1) is provided in chapter 2. As a result we have 1560 patients of which 221
died during the follow-up period. All analyses are based on this population. First we will only
consider NPI (A1- A3) before trying to improve this index by using the full information from
the three NPI components number of nodes, tumor size and tumor grade (A4-A5). Finally we
investigate improvement of the prognostic ability by considering the added value of other stan-
dard variables and by using all available information to derive a MFP model (A6-A8). To com-
pare the discriminative ability of NPI and various variants considered we summarize results
from several measures of discrimination.
Correlation between Factors of Interest
The correlation structure between potential prognostic variables can have a severe influence on
the result of multivariable model building procedures. It is most easily summarized by giving
absolute values of pairwise Spearman rank correlation coefficients. Very large correlations
( 0.7) are observed between NPI and no. of pos. lymph nodes (0.71), NPI and tumor grade
(0.70), as well as age and menopausal status (0.73). In addition, larger (0.5–0.7) and medium
sized (0.3–0.5) correlations are present for NPI and tumor size (0.59) and tumor size and no. of
pos. lymph nodes (0.31), respectively. The absolute value of all other correlation coefficients is
below 0.3 and we consider such values as having only a negligible influence on the result of
multivariable model building.
Discriminative Ability of the NPI Categories
In Fig 1 we show the survival estimates for three and six groups, respectively, derived by catego-
rizing the NPI. With a minor exception for a short term period (up to about 2 years) even the
six groups are well separated over the period of 15 years. Estimates of five-year survival rates
are 95%, 89% and 65% for the three groups from NPI(3) (Table 2). NPI(6) splits each of the
three groups into two separate groups and the resulting estimates (Fig 1 and S2 Table) indicate
much better separation. The two most extreme groups from NPI(6) have estimated five year
survival rates of 97% (EPG) and 48% (VPG), respectively. However, only a small percentage of
the study population belongs to the two extreme groups (10.8%toEPG and 6.3% to VPG).
In Table 3 we give estimates of the hazard ratios from Cox models. For NPI(3) the estimate
of HR for the group with the worst prognosis (NPI> 5.4) compared to the group with the best
prognosis (NPI<3.4) is 4.80. The estimated HR for the two extreme groups from NPI(6) is
14.91. These extreme categories compare the small groups with NPI< = 2.4 with NPI> 6.4.
When interpreting other HR estimates given in Table 3, please note that the reference catego-
ries differ between NPI (3) and NPI(6) analyses. These results illustrate that it is often simple
to derive extremely well separated subgroups and to receive large values for the estimate of the
hazard ratio. Obviously, corresponding subgroups are small, confidence intervals are large and
the clinical relevance of such small subgroups with an extremely good or poor prognosis is lim-
ited. This is also reflected by the small differences of the measures of separation (e.g. the C-
index increases from 0.65 (NPI(3)) to 0.67 (NPI(6)) and R2D as an overall measure derived
from D increase from 0.217 to 0.245; right part of Table 3.).Hence the impression of a much
better separation of NPI(6) compared to NPI(3) based on the Kaplan-Meier plots is misleading.
In addition, it has to be noted that overfitting of the data is likely and results in overestimation
of the difference between the two most extreme subgroups, specifically for the NPI(6)
classification.
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Fig 1. Kaplan-Meier estimates of survival probabilities for prognostic groups defined by the Nottingham Prognostic Index. Top NPI(3)– 3 groups,
below NPI(6)– 6 groups.
doi:10.1371/journal.pone.0149977.g001
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Estimates of the hazard ratio and the measures D with corresponding R2D are derived under
the assumptions of the Cox proportional hazards model. For both classification schemes the
log-log plots (Fig 2 for NPI (3) and S2 Fig for NPI (6)) indicate some minor violations of the
PH assumption at the beginning of the follow-up time. Checking for non-proportionality by
using the fractional polynomial time (FPT) algorithm did not exhibit a significant time-varying
effect. P values of the test for non-proportionality (FP2 function vs. PH) were 0.0647 for NPI
(3) and 0.343 for NPI (6), respectively. Altogether we conclude that the PH assumption is
acceptable.
Extensions of NPI Categories by Using Full Information
Continuous NPI. To avoid problems caused by categorization it may be more suitable to
provide estimates for the continuous variable NPI. The estimated increase in risk for one unit
(e.g. from 3.13 to 4.13 or from 5.09 to 6.09) is 1.67 (see last line of Table 3). Using NPI as a con-
tinuous variable hardly influences the measures for discrimination.
Estimating the effect for the continuous variable NPI we have assumed that a linear function
describes the influence of NPI on our outcome. Using the MFP function selection procedure
and a 5% significance level we have checked that non-linear functions do not improve the fit
Table 2. Survival rates after 5, 10 and 15 years for the categories from NPI(3).
Time Survivor Function Std. Error 95% CI
NPI < 3.4 5 0.954 0.010 [0.930, 0.969]
10 0.912 0.015 [0.878, 0.936]
15 0.876 0.029 [0.807, 0.921]
3.4  NPI  5.4 5 0.891 0.013 [0.862, 0.914]
10 0.794 0.023 [0.745, 0.835]
15 0.753 0.036 [0.673, 0.816]
NPI > 5.4 5 0.652 0.033 [0.584, 0.711]
10 0.574 0.038 [0.495, 0.645]
15 0.542 0.048 [0.444, 0.630]
doi:10.1371/journal.pone.0149977.t002
Table 3. Hazard ratios and discriminative ability of NPI.
Coding log (HR) Hazard Ratio 95% Conﬁdence interval of HR R2D C
NPI (3 categories) NPI < 3.4 0 1 - 0.217 0.651
3.4  NPI  5.4 0.54 1.72 [1.16, 2.55]
NPI > 5.4 1.57 4.80 [3.15, 7.30]
NPI (6 categories) NPI  2.4 0 1 0 0.245 0.673
2.4 < NPI  3.4 0.72 2.06 [0.90, 4.71]
3.4 < NPI  4.4 1.00 2.72 [1.20, 6.17]
4.4 < NPI  5.4 1.24 3.45 [1.51, 7.87]
5.4 < NPI  6.4 1.84 6.32 [2.75, 14.53]
NPI > 6.4 2.70 14.91 [6.42, 34.66]
NPI continuous1 0.51 1.67 [1.49, 1.86] 0.219 0.675
For three version of NPI estimated hazard ratios (left) and measures of the discriminative ability (right) of the standard CoxPH model. All analyses
stratiﬁed by the eight treatment strata (see Table 1)
1 increase of the hazard ratio for one unit
doi:10.1371/journal.pone.0149977.t003
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and that the linearity assumption is acceptable. The test of the proportional hazards assump-
tion did not exhibit any significant violations.
MFP of the three components. The NPI consists of the three components: tumor size, no
of positive lymph nodes and tumor grade. In the original analysis node involvement was cate-
gorized and three groups were considered. The relative weight of each component was esti-
mated as given in the Introduction. Here, we consider a possible improvement of the
prognostic ability by (i) using the full information on the number of positive nodes, (ii) allow-
ing non-linear functions to estimate the effect of the two continuous variable and (iii) re-esti-
mating the relative weights of each of the three variables. In Table 4 we give estimates of the
three components in univariable Cox models assuming a linear effect for tumor size and the
number of positive nodes. Results of the FP analyses show that non-linear functions describe
the functional relationship with the outcome better (in terms of the deviance). The Multivari-
able FP (MFP) approach selects a model with a linear effect for tumor size, a non-linear effect
Fig 2. Log-log plot for NPI(3). Log-log plot to check the proportional hazards assumption of the Cox-model
for three prognostic groups according to NPI(3).
doi:10.1371/journal.pone.0149977.g002
Table 4. Estimated effects of NPI components.
Univariable Multivariable
Linear function FP function MFP model
Coding HR 95% CI HR 95% CI HR 95% CI
Tumor size in cm (linear) 1.18 [1.11, 1.25] 1.11 [1.04, 1.19]
(size)1/2 2.06 [1.58, 2.68]
No. of pos. lymph nodes linear 1.08 [1.06, 1.09]
log(nodes+1) 1.90 [1.65, 2.20]
(nodes+1)-1/2 0.12 [0.07, 0.21]
Tumor grade 1 1 - not relevant 1 -
2 1.72 [1.12, 2.64] not relevant 1 -
3 2.34 [1.52, 3.60] not relevant 1.44 [1.09, 1.91]
Univariable and multivariable Cox PH models assuming a linear effect for continuous variables or choosing the functional form by using the function
selection procedure of the fractional polynomial approach. The signiﬁcance level for both variables and functions is 0.05. All analyses stratiﬁed by the
eight treatment strata (see Table 1)
doi:10.1371/journal.pone.0149977.t004
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for the number of nodes and combines categories 1 and 2 for grade, estimating an increased
risk for grade 3 compared to the others.
For univariable analyses Fig 3 illustrates the difference between the popular approach to
assume a linear functional relationship for a continuous variable and the fractional polynomial
approach which checks whether a non-linear function from the FP class fits the data signifi-
cantly better. Differences indicate that models assuming a linear functional relationship under-
estimate the risk for very low values such as 2 positive nodes or a tumor size of 5 mm and
overestimate the risk (severely) for very large values such as 30 positive nodes or a tumor size
of 100 mm.
Univariable Assessment of the Added Value of Other Standard Factors
In addition to the three NPI components there are six additional standard factors available. In
Table 5 we give estimates of their effects in a univariable model. Age, menopausal status and
histology have no influence on survival time, whereas the effects of the three binary variables
hormone receptor status, vessel invasion and lymphatic vessel invasion are significant at the
5% level. The effect of hormone receptor status is strongest and it is the only effect remaining
significant after adjustment for NPIcont. These results indicate that hormone receptor status is
the only of the six variables which has a significant effect in addition to NPI.
Multivariable Models
The multivariable model given in Table 5 includes NPI and the six additional factors, assuming
linear effects for continuous variables. For an MFP analysis it is the ‘starting’model and the
algorithm investigates simultaneously whether any of the variables can be eliminated and
whether any of the continuous variables have a non-linear effect. This ‘full’model includes sev-
eral variables with a ‘weak’ or no effect and only NPIcont and hormone receptor status are sig-
nificant. Using MFP(0.05, 0.05) to select a simpler model, only NPIcont and hormone receptor
status remain in the model.For NPI a linear function is chosen and the estimated effect is 1.60
(1.43–1.80) per unit increase for NPI. This simple model estimates that hormone receptor posi-
tive tumors have a severely decreased risk of 0.49 (0.37–0.64) compared to receptor negative
tumors.
Fig 3. Functional form for no. of positive nodes for twomodels. Predictor for univariable analysis of no.
of positive lymph nodes derived by two Cox models assuming a linear effect (dashed line) or the significant
improvement from the class of FP models (solid line).
doi:10.1371/journal.pone.0149977.g003
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In Fig 4 we give Kaplan-Meier estimates of survival rates for the six groups derived by a
combination of NPI(3) and receptor status (see also S3 Table). This figure illustrates that recep-
tor status has a strong influence on the survival rate for patients in the worst NPI group (10
year survival rates for receptor positive are 0.69 whereas the corresponding value for receptor
negative patients is 0.44). Over the full observation period survival rates of receptor positive
patients from NPI(3)-3 are very similar to survival rates of receptor negative patients from NPI
(3)-2. For patients from the NPI(3)-2 group hormone receptor status has also a strong influ-
ence on the survival rate (10 year rate is 0.86 for pos and 0.65 for neg), whereas the hormone
receptor effect is small for NPI(3)-1 patients. Estimates at 10 years are 0.92 (pos), 0.89 (neg).
For the NPI(3)-1 group the effect of hormone receptor status seems to vary slightly in time.
To use all information from the nine available variables we repeat the MFP analysis from
above, but consider the three NPI components separately. This analysis would also allow elimi-
nating one or more of the NPI components if they have no significant effect in a multivariable
context. However, all three components remain and hormone receptor is added in the final
model. We propose to use the term extended Nottingham Prognostic Index for this resulting
model and define
NPIext ¼ 0:108  tumor size ðcmÞ þ 0:543  logðno: pos: nodes þ 1Þ
þ 0:404  Ind ðif tumor grade is 2 or 3Þ  0:766  Ind ðif hormone receptor is positiveÞ;
where Ind is the indicator function taking the values 0 (condition is not fulﬁlled) or 1 (condi-
tion is fulﬁlled).
Compared to NPI it adds hormone receptor status as a binary variable, estimates a non-lin-
ear functional influence of the number of positive lymph nodes and weighs the relative influ-
ence of the variables differently (Table 6). The results broadly coincide with the MFP model for
the three NPI components (see Table 4), but the inclusion of hormone receptor status has
Table 5. Estimated effects of additional variables.
Univariable model Multivariable model
Unadjusted Adjusted for NPI*
Coding HR 95% CI HR 95% CI HR 95% CI
NPI continuous 1.67 [1.49, 1.86] * * 1.57 [1.39, 1.77]
Age continuous 1.00 [0.99, 1.01] 1.00 [0.99, 1.01] 0.99 [0.98, 1.01]
Histology invasive ductal 1 - 1 - 1 -
invasive lobular 0.88 [0.53, 1.44] 0.91 [0.55, 1.49] 0.91 [0.55, 1.50]
other 0.64 [0.34, 1.20] 0.74 [0.39, 1.40] 0.66 [0.35, 1.26]
Hormone receptor status negative 1 - 1 - 1 -
positive 0.41 [0.32, 0.54] 0.49 [0.37, 0.64] 0.48 [0.37, 0.63]
Meno- pausal status pre-menopausal 1 - 1 - 1 -
post-menopausal 1.05 [0.78, 1.41] 1.14 [0.85, 1.53] 1.35 [0.89, 2.04]
Vessel invasion V0 1 - 1 - 1 -
V1 1.79 [1.15, 2.78] 1.22 [0.78, 1.92] 1.10 [0.69, 1.76]
Lymphatic vessel invasion L0 1 - 1 - 1 -
L1 1.62 [1.22, 2.17] 1.24 [0.93, 1.66] 1.21 [0.89, 1.64]
Univariable (without and with adjustment) and multivariable (‘full’) CoxPH models. For continuous variables a linear effect is assumed. All analyses
stratiﬁed by the eight treatment strata (see Table 1)
* Estimates for effects of NPI vary slightly (1.60–1.67) for the 6 different models.
doi:10.1371/journal.pone.0149977.t005
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slightly changed the functional form for the number of nodes. Please note that the chosen
power terms are different (-0.5 in Table 4 and 0 (log function) in Table 6), implying that
parameter estimates are very different, but the corresponding functions are very similar (not
presented). The addition of hormone receptor status seems to have the most important influ-
ence on the effect of tumor grading. In the model in Table 4 grade 1 and 2 were collapsed
(meaning that the prognosis of these two categories is identical and only grade 3 has a worse
prognosis) whereas grade 2 was collapsed with 3 in the new model (grade 1 has a better prog-
nosis than the others; see Table 6).
Comparison of Models
To compare performance of various models we give estimates of the C-index, the D-measure
and corresponding R2D for the major’models considered in the paper. Compared to NPI(3)
our final MFP model improves the C-index from 0.651 to 0.714. This notable improvement is a
result of several minor improvements starting with the use of the full NPI information instead
of categorization with three categories, some improvement by using the full information from
the number of positive nodes and the strongest increase comes from adding hormone receptor
status. A similar improvement is indicated by the D-measure and R2D. An improved R
2 value
from 0.217 to 0.290 is substantial (34%), but may to some extent be caused by overfitting the
data. The potential problem of overfitting does not apply to the three models solely depending
Fig 4. Kaplan-Meier curve for combinations of NPI(3) and hormone receptor. NPI groups are defined as
1: NPI<3.4; 2: 3.4NPI5.4; 3: NPI>5.4.
doi:10.1371/journal.pone.0149977.g004
Table 6. MFPmodel.
Coding log (HR) Hazard Ratio 95% Conﬁdence interval of HR
Tumor size in cm (linear) 0.11 1.11 [1.04, 1.19]
No. of pos. lymph nodes log(nodes+1) 0.54 1.72 [1.48, 1.99]
Tumor grade 1 0 1 -
2 and 3 0.40 1.50 [0.99, 2.26]
Hormone receptor negative 0 1 -
positive -0.77 0.46 [0.35, 0.61]
MFP(0.05, 0.05) model for the three individual components of NPI and the six variables v4-v9. Five of these variables are eliminated from the ﬁnal model.
Analysis stratiﬁed by the eight treatment strata (see Table 1)
doi:10.1371/journal.pone.0149977.t006
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on the NPI. By using resampling methods it would be possible to (partly) correct for overopti-
mism, but that is beyond the scope of this paper. Further investigations in a related methodo-
logical paper will allow deriving estimates for the performance measures which are less prone
to overoptimism.
Discussion
In a paper written in a time before the era of genetic information had really started, Sauerbrei
et al [45] stressed the importance of an accepted prognostic model based on standard factors:
‘An important step for an improvement in summarizing information from prognostic factors
would be a widely accepted standard prognostic model. We see the Nottingham Prognostic Index
as the most often validated and accepted classification scheme. As recently published for node-
negative patients where, in addition to changes to the weights of the component of the NPI, in
one of our proposals only age was added to the NPI [24], we see the results from the NPI and our
proposals as a starting point for an urgently needed accepted and sensible description of the influ-
ence of standard factors.’ At that time in breast cancer the prognostic effect of more than 100
factors was discussed controversially and the idea was to have a standard model and to check
whether a new factor improved the separation of prognostic groups derived from a prognostic
model. At least, a standard model would have helped to standardize analyses across studies and
to avoid many claims concerning the relevance of a new prognostic factor. Nowadays, there is
still a controversial discussion concerning factors such as Her2-neu and Ki-67 [52] and since
the intensive research on molecular data, the necessity for a ‘good’ predictive model based on
‘standard’ factors has even increased, at least when clinical usefulness is considered an impor-
tant criterion.
Use and Usefulness of the NPI
The NPI was developed more than 30 years ago using standard information and (from today’s
point of view) a simple approach to derive a Cox model. It is very well validated in many stud-
ies worldwide and oftentimes used in patient care. Beside of some disagreement with point 4,
we fully agree with the synopsis concerning the usefulness of prognostic indices from a group
of authors from Nottingham, some of which belong to the original developers of the NPI [27].
Blamey et al state
‘The NPI has satisfied the criteria which should be applied to all claimed methods for prognos-
tic prediction, namely ability
1. To separate patients into groups with significantly differing survival chances.
2. To achieve wide separation, i.e. to recognise a ‘cured’ group and a group with poor survival.
3. To place a sufficient percentage of cases into each group.
4. To be applicable to all operable breast cancers, i.e. small, screen detected as well as symptom-
atic and those in patients of young age.
5. To have been prospectively validated intra-centre in a new tumour set from that on which it
was derived and intercentre and internationally.
6. To be capable of measurement in all units and inexpensive.’
Because NPI satisfies the most important criteria for a sensible and useful prognostic index,
we consider it as a suitable starting point when trying to derive an improved classification
scheme. Improvement has to be judged by the added value related to a suitable measure of
prognostic separation.
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Potential Improvements of the NPI
Deriving a very simple index with few points and using a simple classification scheme was
important for practical use in the last century. Measures indicate improved separation by
extending the original proposal with three categories (NPI(3)) to six categories (NPI(6)). How-
ever, the weights of the three components tumor size, number of positive nodes and tumor
grade remained unchanged, categorization disregards parts of the relevant information from
continuous data and finally no further factor was added to the NPI in later research.
As in many studies before, the prognostic groups from NPI(3) and NPI(6) separate our
patient population well. However, it is well known that the number of positive lymph nodes is
a prognostic factor with a very strong effect and the NPI uses only a simple classification into
three groups, therefore ignoring a lot of the information from this marker. For example, the
NPI uses the same weight for patients with four and with 25 positive lymph nodes. It is becom-
ing more and more accepted that categorization has severe weaknesses when developing a mul-
tivariable model and that continuous variables should be modelled in a suitable way [45].
Categorization is required for medical decision making but it has severe weakness when deriv-
ing multivariable models. Categorization should be postponed to the final step of developing a
prognostic classification scheme.
By using the full information from the continuous variables tumor size and number of posi-
tive lymph nodes and by adding hormone receptor status, we could improve the prognostic
ability. Compared to many other studies investigating the value of new factors added to the
NPI, our ‘added value’ from the better use of standard factors is much larger. By using three
suitable measures of separation we summarize the information from all ‘major’models in
Table 7. It is well known that scores derived in a data dependent way may be too optimistic
and need validation in independent data [24,36,38]. As all components from our new score are
generally available, validation studies can be easily conducted.
While we concentrated on a more suitable modelling of the data, using a two-step approach
to try to improve the prognostic ability of a score is also possible. Rakha et al [53] started by
using multivariable clustering techniques to identify seven key molecular classes. Within each
class they estimate the effect of several clinicopathological factors in a multivariable Cox
model. Simply by chance the size of the estimate effects varies and a specific factor (say tumor
size) gets a large effect in some of the molecular classes and a small effect in others. For each
molecular class this gives a separate (NPI-type) formula and this complex classification scheme
is called Nottingham Prognostic Index Plus (NPI+). In principle, NPI+ is a very complex index
proposing interactions between the molecular classes and the clinicopathological factors.
Unfortunately it is not possible to assess how much NPI+ improves on NPI(3) or NPI(6) as
Table 7. Summary of ‘major’ models and corresponding measures of separation.
Prognostic factors D R2D C
NPI with 3 categories 1.077 0.217 0.651
NPI with 6 categories 1.165 0.245 0.673
NPI continuous 1.084 0.219 0.675
Tumor size, No. of pos. lymph nodes (transformed), Tumor grade (3 vs. 1/2) 1.158 0.243 0.677
NPI, Age, Histology, Hormone receptor status, Menopausal status, Vessel
invasion,Lymphatic vessel invasion
1.268 0.277 0.706
NPI, Hormone receptor status 1.231 0.266 0.707
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presentation of results is restricted to Kaplan-Meier plots for survival time. Measures of the dis-
criminative ability of the indices are not given.
For many years NPI(3) has been used for decision making in clinical practice. Barton et al
[52] investigated for agreement between risk categorizations by NPI(3) and the IHC4+C score
(also categorized into 3 groups). Risk classifications (low, medium, high) agreed in 60.4%.
Studies with access to relevant data of the IHC4+C score could check whether our modified
NPI index agrees better with the IHC4+C score, specifically differences in the NPI(medium)
category are severe. However, differences in risk classifications do not directly imply different
treatments for patients. The comparisons of treatments require randomized trials and the
importance of risk classifications for treatment decisions needs investigations in relevant sub-
groups and corresponding tests for interaction with treatment.
Methodological Issues
Compared to the methodology for multivariable model building at the time the NPI was devel-
oped, statistical methodology has seen severe improvements. Unfortunately, many of these
developments are ignored in practice [54]. In addition, reporting of many studies in the health
sciences is insufficient and incomplete [36,38], making the assessment of results difficult. By
providing a REMARK type profile [38] we give details about our patient population, illustrate
all steps of our model development and assessment and refer to some highly relevant checks of
important assumptions of the Cox model. Unfortunately, there are no generally accepted state-
of-the-art analyses and measures [54]. For many years some of us have worked in this area and
we used our preferred approaches. We are well aware that the results are too optimistic if
model development and model assessment are based on the same data. Therefore we expect
that the added value of our new proposal is slightly overestimated. This and several other rele-
vant methodological issues will be discussed in a follow-up paper.
Summary
Using improved statistical methodology and generally available standard information we pro-
pose to slightly extend the NPI. Using the full information from continuous variables we derive
the index
NPIext ¼ 0:108  tumor size ðcmÞ þ 0:543  logðno: pos: nodes þ 1Þ
þ 0:404  Ind ðif tumor grade is 2 or 3Þ 0:766  Ind ðif hormone receptor is positiveÞ
which leads to an important increase in its prognostic ability and a related classiﬁcation scheme
can be easily derived and generally used for patient handling.
Most of the statistical issues illustrated in the context of breast cancer and the Nottingham
Prognostic Index apply in a similar manner to other projects aiming to derive a prognostic
index for a survival time outcome. To better illustrate which analyses and checks of assump-
tions are relevant we summarize all steps conducted in a REMARK type profile (Altman, [38]).
We propose to use such an approach to derive a suitable measure summarizing the information
from standard factors in other diseases.
Conclusion
Using the well-established NPI as an example, we show that it is possible to derive an extended
index NPIext with substantially improved prognostic ability. Using more sophisticated statisti-
cal methodology we propose to weight tumor size, no of positive nodes and tumor grade differ-
ently and to add hormone receptor status. As all four prognostic markers are available for most
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breast cancer patients, it can be used for patient management worldwide. For prognostic
research in breast cancer, it can be used to summarize standard clinical information, also serv-
ing as a benchmark to assess the added value of new clinical or molecular markers in single
studies as well as in the assessment of a marker or a genomic signature in meta-analysis. Statis-
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